Die Behandlung von bipolaren Störungen nach den Leitlinien des Canadian Network for Mood and Anxiety Treatments

D. Giersch; I. von Stralendorff; W. Greil

doi:10.1055/s-0038-1627169

Nervenheilkunde, Table of Contents

Nervenheilkunde 2008; 27(03): 133-144
DOI: 10.1055/s-0038-1627169

Original- und Übersichtsarbeiten - Original and Review Articles

Schattauer GmbH

Die Behandlung von bipolaren Störungen nach den Leitlinien des Canadian Network for Mood and Anxiety Treatments

Stand Update 2007Pharmacological treatment of bipolar disorders according to the guidelines of the Canadian Network for Mood and Anxiety Treatments, Update 2007

D. Giersch

¹Klinikum der Ludwig-Maximilians-Universität München, Klinik für Psychiatrie und Psychotherapie (Leiter: Prof. Dr. H.-J. Möller)

,

I. von Stralendorff

¹Klinikum der Ludwig-Maximilians-Universität München, Klinik für Psychiatrie und Psychotherapie (Leiter: Prof. Dr. H.-J. Möller)

,

W. Greil

¹Klinikum der Ludwig-Maximilians-Universität München, Klinik für Psychiatrie und Psychotherapie (Leiter: Prof. Dr. H.-J. Möller)

› Author Affiliations

Abstract

Zusammenfassung

Für die Behandlung bipolarer Störungen wurden von unterschiedlichen Arbeitsgruppen evidenzbasierte Leitlinien herausgegeben, bei denen die verschiedenen diagnostischen Untergruppen sowie die verschiedenen Behandlungsphasen berücksichtigt werden. Besonders aktuell und umfassend sind die Leitlinien des Canadian Network for Mood and Anxiety Treatments (CANMAT). Die dort gegebenen Empfehlungen begründen sich nicht nur auf den Evidenzgrad mit der jeweiligen Substanz, sondern beziehen auch Daten zur Sicherheit und Verträglichkeit sowie allgemeine klinische Erfahrungen mit ein. In diesem Beitrag werden die Empfehlungen des CANMAT aus den Leitlinien 2005 und dem Update 2007 zusammengefasst und kurz kommentiert.

Summary

Different authors have developed evidence-based guidelines which refer to various aspects of the diagnostic spectrum as well as the course of treatment of bipolar disorders. The current and comprehensive guidelines of the Canadian Network for Mood and Anxiety Treatments (CANMAT) are based on evidence as well as safety and tolerance issues. This article summarizes the guidelines 2005 and the update 2007 and gives a short comment.

Schlüsselwörter

Bipolare Störung - Pharmakotherapie - Stimmungsstabilisierer - Leitlinien

Keywords

Bipolar disorder - pharmacological treatment - mood stabilizers - guidelines

Full Text

References

Literatur
1 Ahrens B, Müller-Oerlinghausen B. Does lithium exert an independent antisuicidal effect?. Pharmacopsychiatry 2001; 34: 132-136.
2 Ahrens B. et al. Extended survival of patients on long-term lithium treatment. Canadian journal of psychiatry 1995; 40: 241-246.
3 Altschuler LL. et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. American journal of psychiatry 1995; 152 (Suppl. 08) 1130-1138.
4 Baker RW. et al. Acute dysphoric mania: treatment response to olanzapine versus placebo. Journal of clinical psychopharmacology 2003; 23 (Suppl. 02) 132-137.
5 Baldessarini RJ. et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. Journal of clinical psychopharmacology 2003; 23 (Suppl. 04) 370-376.
6 Baldessarini RJ. et al. Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar I and II disorder patients. Journal of affective disorders 2000; 61: 13-22.
7 Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of clinical psychiatry 2003; 64: 403-407.
8 Battaglia J. et al. Calming versus sedative effects of intramuscular olanzapine in agitated patients. American journal of emergency medicine 2003; 21 (Suppl. 03) 192-198.
9 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. International clinical psychopharmacology 1999; 14 (Suppl. 06) 339-343.
10 Bottlender et al. Antidepressant-associated maniform states in acute treatment of patients with bipolar- I-depression. European archives of psychiatry and clinical neuroscience 1998; 248 (Suppl. 06) 269-300.
11 Bowden CL. Clinical correlates of therapeutic response in bipolar disorder. Journal of affective disorders 2001; 67 1-3 257-265.
12 Bowden CL. et al. Efficacy of divalproex versus lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271 (Suppl. 12) 918-924.
13 Bowden CL. A placebo-controlled 18-months trial of lamotrigine and lithium maintencance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of general psychiatry 2003; 60 (Suppl. 04) 392-400.
14 Bowden CL. et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. Journal of clinical psychiatry 2005; 66 (Suppl. 01) 111-21.
15 Calabrese JR. et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of clinical psychiatry 2003; 64 (Suppl. 09) 1013-1024.
16 Calabrese JR. et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. Journal of clinical psychiatry 1999; 60 (Suppl. 02) 79-88.
17 Calabrese JR. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American journal of psychiatry 2005; 162 (Suppl. 07) 1351-1360.
18 Calabrese JR. et al. Current research on rapid cycling bipolar disorders and its treatment. Journal of affective disorders 2001; 67: 241-255.
19 Calabrese JR. et al. A 20-months, double-blind, maintenance trial of lithium versus divalproex in rapid cycling bipolar disorder. American journal of psychiatry 2005; 162 (Suppl. 11) 2152-2161.
20 Calabrese J. et al. Predictors of valproate response in biplar rapid cycling. Journal of clinical psychopharmacology 1993; 13 (Suppl. 04) 280-283.
21 Cipriani A. et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162 (Suppl. 10) 1805-1819.
22 Coppen A. et al. Does lithium reduce the mortality of recurrent mood disorders?. Journal of affective disorders 1991; 23: 1-7.
23 Coppen A, Farmer R. Suicide mortality in patients on lithium maintenace therapy. Journal of affective disorders 1998; 50: 261-267.
24 Currier GW. et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepame versus intramusculuar treatment with haloperidol and lorazepam. Journal of clinical psychiatry 2004; 65 (Suppl. 03) 386-94.
25 Delbello MP. et al. A double-blind, randomized, placebo-controlled study of quetiapine as adunctive treatment for adolescent mania. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41 (Suppl. 10) 1216-1223.
26 Devanand DP. et al. The efficacy of ECT in mixed affective states. Journal of ECT 2000; 16 (Suppl. 01) 32-37.
27 Donnelly EF. et al. Prediction of antidepressant responses to lithium. American journal of psychiatry 1978; 135: 552-556.
28 Erfurth A, Dobmeier M, Zechendorf M. Kurzpsychoedukation für bipolare Patienten. Das einfache Kurzprogramm in 6 Modulen. Stuttgart: Thieme Verlag; 2005
29 Foster S. et al. Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. International clinical psychopharmacology 1997; 12 (Suppl. 03) 175-179.
30 Freeman TW. et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. American journal of psychiatry 1992; 149 (Suppl. 01) 108-111.
31 Frye MA. et al. A placebo-controlled study of lamotrigine and gabapentine monotherapy in refractory mood disorders. Journal of clinical psychopharmacology 2000; 20 (Suppl. 06) 607-614.
32 Gjisman HJ. et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. American Journal of psychiatry 2004; 161 (Suppl. 09) 1537-1547.
33 A multicenter, double-blind, placebo-controlled, flexible-dose evaluation of the safety and efficacy of lamotrigine in the long term treatment of subjects who have bipolar disorder with rapid cycling: GlaxoSmithKline Clinical Trial Register. Aug 18 2005 http://ctr.gsk.co.uk/Summary/lamotrigine/II_SCAB2005.pdf [accessed on 24 Nov 2007].
34 Goldsmith DR. et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050.
35 Gonzalez-Pinto A. et al. Treatment of bipolar I rapid cycling during dysphoric mania with olanzapine. Journal of clinical psychopharmacology 2002; 22 (Suppl. 05) 450-454.
36 Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of psychopharmacolog 2003; 17 (Suppl. 02) 149-173.
37 Goodwin GM. et al. A pooled analyses of 2 placebo- controlled 18-months trials of lamotrigine and lithium maintenance in bipolar I disorder. Journal of clinical psychiatry 2004; 65 (Suppl. 03) 434-441.
38 Goodwin GM. et al. Lithium response in unipolar versus bipolar depression. American journal of psychiatry 1972; 129: 44-47.
39 Greil W, Giersch D. Stimmungsstabilisierende Therapien bei manisch-depressiven (bipolaren) Erkrankungen. Stuttgart: Thieme Verlag; 2002
40 Greil W. et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of clinical psychopharmacology 1998; 18 (Suppl. 06) 455-460.
41 Grunze H. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part I: Treatment of bipolar depression. World journal of biological psychiatry 2002; 3 (Suppl. 03) 115-124.
42 Grunze H. et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders, part II: Treatment of mania. World journal of biological psychiatry 2002; 4 (Suppl. 01) 5-13.
43 Guzzetta F. et al. Lithium treatment reduces suicide risk in recurrent major depressive disorder. Journal of clinical psychiatry 2007; 68 (Suppl. 03) 380-3.
44 Hirschfeld RMA. et al. Practice guideline for the treatment of patients with bipolar disorder (revision). American journal of psychiatry 2002; 159 (Suppl. 04) 1-50.
45 Hirschfeld RM. et al. Rapid antimanic effect of risperidone montherapy: a 3-week multicenter, double- blind, placebo-controlled trial. American journal of psychiatry 2004; 161 (Suppl. 06) 1057-1065.
46 Hirschfeld RM. et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double- blind, placebo-controlled study. Journal of clinical psychiatry 2006; 67 (Suppl. 03) 355-362.
47 Jacobsen FM. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. Journal of clinical psychiatry 1993; 54 (Suppl. 06) 229-234.
48 Keck Jr PE. et al. A placebo-controlled, doubleblind study of the efficacy and safety of aripiprazole in patients with acute mania. American journal of psychiatry 2003; 160 (Suppl. 09) 1651-1658.
49 Keck Jr PE. et al. A review of randomized, controlled clinical trials in acute mania. Journal of affective disorders 2000; 59 (Suppl. 01) S31-S37.
50 Keck Jr PE. et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. American journal of psychiatry 2003; 160 (Suppl. 04) 741-748.
51 Khanna S. et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. British Journal of psychiatry 2005; 187: 229-234.
52 Kilzie N, Akiskal H. Rapid Cycling bipolar disorder. An overview of research and clinical experience. Psychiatric clinics of North America 1999; 22: 585-607.
53 Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar disorders 2005; 7 (Suppl. 05) 404-17.
54 Kukopulos A. et al. Course of the manic-depressive cycle and changes caused by treatment. Pharmakopsychiatry and Neuropsychopharmacology 1980; 13: 156-167.
55 Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. Journal of clinical psychiatry 2002; 63 (Suppl. 10) 23-28.
56 Kusumakar V. et al. Treatment of mania, mixed state, and rapid cycling. Canadian Journal of Psychiatry 1997; 42 (Suppl. 02) S79-S86.
57 Lambert P, Venaud G. Comparative study of vapromide versus lithium in treatment of affective disorders. 1992; 5: 57-65.
58 Leverich GS. et al. Risk of switch in mood polarity to hypomania or mania in patients with with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropione as adjuncts to mood stabilizers. American journal of psychiatry 2006; 163: 232-239.
59 MacQueen GM. et al. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatrica Scandinavica 2000; 101 (Suppl. 05) 374-381.
60 Macritchie K. et al. Valproate for acute mood episodes in bipolar disorders. Cochrane Database Systematic Reviews 2003; 1: CD004052.
61 McIntyre RS. et al. Quetiapine or haloperidon as monotherapy for bipolar mania - a 12 week, double- blind, randomised, parallel-group, placebocontrolled trial. European Neuropsychopharmacology 2005; 15 (Suppl. 05) 573-585.
62 Meehan K. et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of clinical psychopharmacology 2001; 21 (Suppl. 04) 389-397.
63 Okuma T. et al. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Pharmacology (Berl) 1981; 73 (Suppl. 01) 95-96.
64 Perlis RH. et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of clinical psychiatry 2006; 67 (Suppl. 04) 509-516.
65 Pope Jr HG. et al. Valproate in the treatment of acute mania. A placeo-controlled study. Archives of general psychiatry 1991; 48 (Suppl. 01) 62-68.
66 Post R. et al. Morbidity in 258 bipolar outpatients followed for 1 year with dailyprospective ratings on the NIMH life chart method. Journal of clinical psychiatry 2003; 64: 680-90.
67 Potkin SG. et al. Ziprasidone in acute bipolar mania: a 21-randomized, double-blind, placebo-controlled replication trial. Journal of clinical psychopharmacology 2005; 25 (Suppl. 04) 301-310.
68 Sachs G. et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorders: a 3-weeks placebo-controlled study. Journal of psychopharmacology 2006; 20 (Suppl. 04) 536-546.
69 Sachs GS. et al. Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression. New England Journal of Medicine 2007; 356: 1711-1722.
70 Sajatovic M, Davies M, Hrouda D. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatric Services 2004; 55: 264-269.
71 Sanger TM. et al. Olanzapine in the acute treatment of bipolare I disorder with a history of rapid cycling. Journal of affective disorders 2003; 73: 155-161.
72 Scherk H, Pajonk F, Leucht S. Review: Adding second generation antipsychotics to mood stabilisers reduces acute mania symptoms. Evidence Based Mental Health 2007; 10 (Suppl. 04) 111.
73 Secunda SK. et al. Mania. Diagnosis, state measurement and prediction of treatment response. Journal of affective disorders 1985; 8 (Suppl. 02) 113-121.
74 Sharma V. et al. Treatment of Rapid Cycling bipolar disorder with combination therapy of valproate and lithium. Canadian journal of psychiatry 1993; 38: 137-139.
75 Silverstone PH, Silverstone T. A review of acute treatments for bipolar depression. International clinical psychopharmacology 2004; 19 (Suppl. 03) 113-124.
76 Smulevich AB. et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-weed placebo- controlled trial followed by a 9-week placebocontrolled trial followed by a 9-week double-blind trial of risperidone and haloperidol. European neuropsychopharmacology 2005; 15 (Suppl. 01) 75-84.
77 Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depresseion: a meta-analysis. British journal of psychiatry 1991; 158: 666-675.
78 Swann AC. et al. Depression during mania. Treatment response to lithium or divalproex. Archives of general psychiatry 1997; 54 (Suppl. 01) 37-42.
79 Thase ME. et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of clinical psychopharmacology 2006; 26 (Suppl. 06) 600-609.
80 Tohen M. et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American journal of psychiatry 2006; 163 (Suppl. 02) 247-256.
81 Tohen M. et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. American journal of psychiatry 2005; 162 (Suppl. 07) 1281-1290.
82 Tohen M. et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Archives of general psychiatry 2000; 57 (Suppl. 09) 841-849.
83 Tohen M. et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of memission: a 47-week study. American journal of psychiatry 2003; 160 (Suppl. 07) 1263-1271.
84 Tohen M. et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. American journal of psychiatry 1999; 156 (Suppl. 05) 702-709.
85 Tondo L, Hennen J, Baldessarini R. Rapid Cycling bipolar disorder: effects of long-term treatments. Acta psychiatrica scandinavica 2003; 108: 4-14.
86 Vieta E. et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. Journal of clinical psychiatry 2002; 63: 508-512.
87 Vieta E. et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis oft wo international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005; 21 (Suppl. 06) 923-934.
88 Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G. European perspective on the Canadian guidelines for bipolar disorder. Bipolar disorders 2005; 7 (Suppl. 03) 73-76.
89 Volz HP, Sauer H. Behandlung der aktuen Manie mit Lithium und anderen Pharmaka. in Müller-Oerlinghausen B, Greil W, und Berghöfer A. (Hrsg.). Die Lithiumtherapie. Nutzen, Risiken, Alternativen. Berlin: Springer; 1997: 163-177.
90 Weisler RH. et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, doubleblind, placebo-controlled trials. CNS Drugs 2006; 20 (Suppl. 03) 219-231.
91 Weisler RH, Kalaki H, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. Journal of clinical psychiatry 2004; 65 (Suppl. 04) 478-484.
92 Weisler RH. et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicanter, randomized, doubleblind, placebo-controlled trial. Journal of clinical psychiatry 2005; 66 (Suppl. 03) 323-330.
93 Wolfsperger M. et al. Pharmacological treatment of acute mania in psychiatric in-patients between 1994 and 2004. Journal of Affective Disorders 2007; 99 1-3 9-17.
94 Worrall EP. et al. Controlled studies of the acute antidepressant effects of lithium. British journal of psychiatry 1979; 135: 255-262.
95 Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar disorders 2003; 5 (Suppl. 02) 7-19.
96 Yatham LH. et al. Canadian Netword for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar disorders 2005; 7 (Suppl. 03) 5-69.
97 Yatham LH. et al. Canadian Netword for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar disorders 2006; 8 (Suppl. 06) 721-739.